Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Acute pain is a significant factor for patients with hidradenitis suppurativa (HS) that can be reduced by treating the inflammation associated with this disease, says Jeff Stark, MD, vice president, head of medical immunology, UCB.
Transcript
What specific improvements in skin pain were observed in patients with hidradenitis suppurative (HS) treated with bimuzkizumab-bkzx compared with placebo?
We're very excited about the skin pain results that we're presenting here for bimekizumab at the AAD meeting [American Academy of Dermatology Annual Meeting 2024]. Bimekizumab, as you may know or your listeners may know, is a novel molecule that targets 2 different components of the IL [interleukin]-17 pathway, both IL-17A and IL-17F, both of which we know are potent drivers of inflammation in inflammatory skin diseases like Hidradenitis suppurativa.
We've previously presented our pain results in HS, but are now looking at longer-term data, specifically from week 16 onto week 48. We saw rapid reductions in pain previously in that week 16 segment of the data, which was the placebo-controlled data. Now we're looking at more long-term open label extension data and are very pleased to see that we are observing continued improvements in pain that follow on to that rapid reduction over 16 weeks. Those patients who continue to bimekizumab or who switch to bimekizumab from placebo at week 16 continue to experience longer-term reductions in pain as well.
The reason I think this is exciting is really 2 reasons. One is that these are longer-term data that helps us to know what to expect as patients are treated with bimekizumab over longer periods of time. Also, because pain is among the most prominent symptoms that patients with HS experience, and so, to be able to speak to their experience with the disease and demonstrate effectiveness of a therapy to reduce that prominent symptom for them is particularly exciting as well.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More